June 2011

Duloxetine and Venlafaxine: Where They Fit in an MDD Treatment Algorithm
There is no evidence that SNRIs are superior to SSRIs for the treatment of depression.

Ziprasidone Enhances Weight Loss in Patients with Bipolar Disorder
Adjunctive ziprasidone (Geodon) may help facilitate weight loss in overweight patients with bipolar disorder.

Lamotrigine Fails as an Augmenter in TRD
The first large trial of adjunctive lamotrigine (Lamictal and others) for treatment-resistant depression failed to find a statistically significant advantage of lamotrigine over placebo.

In Brief
Treatments for autism spectrum disorders are reviewed.

Light Therapy for Depression during Pregnancy
A small study found significant benefit for bright light therapy for pregnant women with depression.

Reboxetine: Less than Meets the Eye
A review and meta-analysis found reboxetine less effective than SSRIs for the acute treatment of depression and more likely than placebo to cause adverse effects.

Reboxetine: Less than Meets the Eye

June 2011

Reboxetine is a selective-norepinephrine reuptake inhibitor (SNRI) available for the treatment of major depressive disorder (MDD) in many countries but not in the United States. Patients in the United States, however, sometimes go abroad or use the Internet to get this drug. Now comes word that reboxetine…

To view the rest of this article, please: